By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Southern Research Institute 

431 Aviation Way

Frederick  Maryland  21701  U.S.A.
Phone: 301-694-3232 Fax: 301-694-7223


SEARCH JOBS
Southern Research is a full service contract research organization that provides quality essential services in preclinical drug discovery and development. Working as science-centered, client-focused partners with its pharmaceutical and biotechnology clients, and government sponsors, Southern Research continues to demonstrate research excellence and partnering value in the search for tomorrow's breakthrough discoveries.

Southern Research scientists conduct preclinical research primarily in cancer, infectious diseases, emerging biological threat agents, and CNS disorders; earning an enviable track record in getting drugs to clinic. Twenty-two Southern Research discoveries have gone into clinical trials, resulting in six FDA approved anti-cancer drugs now on the market with four additional drugs now in clinical trials. Southern Research has also screened approximately 80% of all other FDA approved cancer drugs, as well as 75% of all approved antivirals.

The company, chartered in 1941, employs more than 600 scientists, technicians and support staff. The company's primary pharmaceutical research facilities are located in Birmingham, Alabama and Frederick, Maryland where their services include:

  • Basic and contract drug discovery services
  • Antiviral drug discovery, specializing in HIV and Hepatitis
  • Vaccine and immunology evaluation (HIV and BioThreat agents)
  • In vitro and in vivo services
  • ADME/PK and gene therapy safety
  • Toxicology
  • Bioanalytical services

    Southern Research Institute's FDA approved cancer drugs are:
  • Amifostine (marketed by MedImmune)
  • Fludarabine (marketed by Berlex)
  • Dacarbazine (marketed by Merck)
  • Lomustine (marketed by Bristol-Myers-Squibb)
  • Carmustine (marketed by Bristol-Myers-Squibb)
  • Clofarabine (marketed by Bioenvision and Genzyme)

    Anti-cancer drug discoveries currently in clinical trials are:
  • PDX (licensed to Allos Therapeutics)
  • 4'-Thio-Ara-C (licensed to OSI)
  • DMPEN (licensed to Xanthus Life Sciences)
  • Isophosporamide Mustard (licensed to DEKK TEC)

    Key Management (Maryland):

  • Robert C. Lonergan, President and CEO
  • Tina S. Rogers, Ph.D., Vice President, Drug Development Division
  • Michael G. Murray, Director, Southern Research Institute, Frederick
  • David R. Harris, Director, Business Development
  • Rhonda S. Jung, Director, Public Relations

    For more information about Southern Research and its research services, please visit www.southernreseach.org, or contact David Harris at d.harris@sri.org (205-581-2343.)
    development problem".

    Last Updated: 04-11-05

    Key Statistics


    Email:
    Ownership: Subsidiary

    Web Site: Southern Research Institute
    Employees: Frederick location - 65
    Symbol: 
     



  • Industry
    Services






    Company News
    Southern Research Institute And University of Alabama at Birmingham Partner To Develop Life-Changing Medical Devices 11/4/2014 9:43:01 AM
    Southern Research Institute Names Corinne Augelli-Szafran, Ph.D., Director Of Chemistry 6/17/2014 12:43:16 PM
    Southern Research Institute To Exhibit At 2014 American Association of Pharmaceutical Scientists National Biotechnology Conference 5/5/2014 11:49:25 AM
    Southern Research Institute Invited To Present At ESTRO 33 Meeting 4/7/2014 6:48:35 AM
    Southern Research Institute CEO Arthur J. Tipton Named A Fellow In The National Academy Of Inventors 12/10/2013 9:55:46 AM
    Southern Research Institute Selected to Evaluate Long-Term Health Effects of Early Life Chemical Exposures for the National Toxicology Program (NTP) 10/2/2013 10:08:54 AM
    Arthur J. Tipton, Ph.D. Appointed New CEO at Southern Research Institute 6/18/2013 6:56:32 AM
    Company Profile for Southern Research Institute 10/26/2012 8:56:21 AM
    Southern Research Institute Continues to Play a Role in U.S. Government’s Program to Make World Safer 10/26/2012 7:41:02 AM
    Understanding the Cause and Prevention of Birth Defects: Southern Research Institute's DART Program Conducts Critical Reproductive Toxicology Work 8/21/2012 9:42:43 AM
    1234567
    //-->